Brief: Targovax's Oncos-102 Mesothelioma 24-Month Data Shows Class-Leading Median Overall Survival

Circio Holding ASA

10/06/2021 12:49

June 10 (Reuters) - Targovax ASA  TRVX.OL :
    * TARGOVAX'S ONCOS-102 MESOTHELIOMA 24-MONTH DATA SHOWS
CLASS-LEADING MEDIAN OVERALL SURVIVAL
    * TARGOVAX ASA - MEDIAN OVERALL SURVIVAL (MOS) FOR
FIRST-LINE
TREATMENT WITH ONCOS-102 PLUS CHEMOTHERAPY WILL BE BETWEEN 21.9
AND 25.0 MONTHS

Source text for Eikon:  ID:nPnbDnw3la 
Further company coverage:  TRVX.OL 

 ((Reuters.Briefs@thomsonreuters.com;))